Technical Analysis for ANL - Adlai Nortye Ltd.

Grade Last Price % Change Price Change
D 11.26 -0.88% -0.10
ANL closed down 0.88 percent on Friday, December 8, 2023, on 17 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Up

Date Alert Name Type % Chg
180 Bullish Setup Bullish Swing Setup 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Overbought Stochastic Strength 0.00%
Gapped Down Weakness 0.00%
Shooting Star Candlestick Bearish -0.88%
Lizard Bearish Bearish Day Trade Setup -0.88%
Gilligan's Island Sell Setup Bearish Swing Setup -0.88%
Pocket Pivot Bullish Swing Setup -0.88%
Doji - Bearish? Reversal -0.88%
Wide Bands Range Expansion -0.88%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 2 days ago
60 Minute Opening Range Breakout 2 days ago
Gapped Down (Full) 2 days ago
Down 5% 2 days ago
Down 3% 2 days ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Adlai Nortye Ltd. Description

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule EP4 antagonist to modulate the tumor microenvironment; and AN4005, an oral small-molecule PD-L1 inhibitor to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and APC modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was incorporated in 2018 and is based in Grand Cayman, the Cayman Islands.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Immune System Tumor Cancer Immunotherapy Cancer Therapies Checkpoint Inhibitor Clusters Of Differentiation Tumor Microenvironment Programmed Cell Death Protein 1

Is ANL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 19.2999
52 Week Low 7.82
Average Volume 8,883
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 10.27
10-Day Moving Average 10.88
Average True Range 0.51
RSI (14) 60.16
ADX 23.77
+DI 28.78
-DI 27.35
Chandelier Exit (Long, 3 ATRs) 10.32
Chandelier Exit (Short, 3 ATRs) 9.66
Upper Bollinger Bands 11.80
Lower Bollinger Band 8.74
Percent B (%b) 0.82
BandWidth 29.79
MACD Line 0.41
MACD Signal Line 0.26
MACD Histogram 0.1515
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.25
Resistance 3 (R3) 12.14 11.70 12.09
Resistance 2 (R2) 11.70 11.45 11.76 12.03
Resistance 1 (R1) 11.48 11.29 11.59 11.59 11.97
Pivot Point 11.04 11.04 11.10 11.10 11.04
Support 1 (S1) 10.82 10.79 10.93 10.93 10.55
Support 2 (S2) 10.38 10.63 10.44 10.49
Support 3 (S3) 10.16 10.38 10.44
Support 4 (S4) 10.27